Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
5(83.3%)
Phase 2
1(16.7%)
6Total
Phase 1(5)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07499102Phase 2Not Yet Recruiting

CK0801 for Treatment of Aplastic Anemia

Role: lead

NCT03773393Phase 1Active Not Recruiting

A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)

Role: lead

NCT05423691Phase 1Recruiting

Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

Role: lead

NCT05695521Phase 1Active Not Recruiting

Regulatory T Cells for Amyotrophic Lateral Sclerosis

Role: lead

NCT03773328Phase 1Withdrawn

A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-Barré Syndrome (GBS)

Role: lead

NCT04468971Phase 1Completed

REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia

Role: lead

All 6 trials loaded